[Skip to Content]
[Skip to Content Landing]
Views 491
Citations 0
Comment & Response
August 4, 2020

Intravenous Interferon β-1a for Severe ARDS

Author Affiliations
  • 1Emergency Department, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China
JAMA. 2020;324(5):515. doi:10.1001/jama.2020.7980

To the Editor Dr Ranieri and colleagues1 found that intravenous interferon (IFN) β-1a administered for 6 days, compared with placebo, did not result in significant improvement in a composite score that included death and ventilator-free days over a total of 28 days in patients with acute respiratory distress syndrome (ARDS). Some important issues remain to be discussed.